To: Recipients of M62, 1st ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
       Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of a correction made to CLSI document M62, *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*, 1st ed. The correction is described below and shown as highlighted and/or stricken text in the table excerpt.

**Table 6. Antimycobacterial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria:**

The doxycycline row is missing a footnote. It has been corrected to include a footnote (†) that reads “Minocycline can be substituted.” Existing footnote symbols have been updated as needed throughout the table and in the footnotes list below the table.

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th>MIC, µg/mL</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxycycline†</td>
<td>≤1</td>
<td>2-4</td>
</tr>
</tbody>
</table>

*ATCC® is a registered trademark of the American Type Culture Collection.
† Minocycline can be substituted.
‡ The *M. fortuitum* group includes *M. fortuitum*, *M. peregrinum*, *M. senegalense*, *M. setense*, *M. septicum*, *M. porcinum*, *M. houstonense*, *M. boenickei*, *M. brisbanense*, and *M. neworleansense*.
§ The *M. smegmatis* group includes *M. smegmatis* and *M. goodii*.
†† The *M. mucogenicum* group includes *M. mucogenicum*, *M. aubagnense*, and *M. phocaicum*.

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.